Introduction
LKM-1 autoantibodies are found in a subgroup of patients with idiopathic autoimmune chronic hepatitis (1) . These antibodies recognize P450IID6, a cytochrome P-450 monooxygenase, as judged by their recognition of the protein expressed from cDNAs as a fusion protein (3, 4) and by the capacity of the antibodies to inhibit reactions catalyzed by P4501ID6 (5) . P4501ID6 is associated with the metabolism of debrisoquine and other antihypertensive drugs, and defective alleles of the gene encoding P4501ID6 occur frequently leading to deficiencies in the metabolism of these compounds in roughly 5-10% ofCaucasians (6) . Competitive binding assays described in earlier studies indicated that LKM-1 antibodies from different patients bound to overlapping epitopes on P450IID6 (7) . These antibodies recognize both the native enzyme in microsomes as well as the denatured protein in immunoblots, and the latter suggested that these antibodies might recognize a linear segment of the protein.
The present study was undertaken to determine whether these antibodies recognize a linear segment ofP450IID6 and to characterize the location and sequence of the immunoreactive segment. We reasoned that this effort would confirm the uniformity of LKM-I autoreactivity as well as identify other proteins exhibiting similar amino acid sequences that might also react with these antisera. In addition, the identification ofan epitope recognized by these inhibitory antibodies could provide additional information regarding the topology of P450 proteins. We report here the identification of a short segment of P450IID6 that is recognized by almost all LKM-1 autoantibodies.
Methods
Patient sera. 26 LKM-1 positive sera from patients with hepatitis B surface antigen-negative chronic active hepatitis were the focus of this study. These sera were classified as LKM-12 positive because of their reactivity by indirect immunofluorescence on rodent liver and kidney tissue sections as well as by positive immunoblots of human liver microsomes and human recombinant LKM-1 (P4501ID6) antigen (3) . As controls, we used sera from nine patients with primary biliary cirrhosis which were positive for anti-mitochondrial antibodies and sera from six healthy controls without evidence of liver disease.
Construction ofdeletion mutants. The HLD8.2 cDNA (3) was inserted into the EcoRI site ofpBluescript KS-(Stratagene, Inc., La Jolla, CA). The construct was digested with Clal, and the overhangs were filled-in using Klenow fragment, in order to place the insert in proper reading frame. Transformants ofDH5a cells (Bethesda Research Laboratories, Gaithersburg, MD) harboring this construct expressed a protein which reacted strongly with an LKM-1 positive serum using the immunoscreening procedure described by Helfman et al. (8) . Sequence analysis confirmed that the orientation of the insert was correct and that the reading frame of the insert extended that of ,B-galactosidase.
Initial mutants were made by deleting a 3' segment or an internal portion of the coding sequence using the restriction enzymes shown in the legend to Fig. 1 . In other cases, an internal restriction fragment was excised and inserted into pBluescript KS- This restriction fragment to-DLTEAFLA C8-MER gether with shorter synthetic fragments were inserted into pATH for expression as fusion proteins with 336-amino acid amino-terminal segments of anthranilate synthetase in E. coli. The amino acid sequences of P4501ID6 encoded by these constructs are shown. These were analyzed by immunoblotting as shown in Fig. 2 .
blunt-ended sites in the polylinker and cDNA were used or created by filling in 5' or making flush 3' overhangs at the selected site using Klenow fragment or T4-DNA polymerase (U.S. Biochemical Corp., Cleveland, OH) respectively. The 5' junction of the insert and polylinker region were sequenced to confirm orientation and reading frame.
Construction ofa synthetic cDNA encoding the epitope. The following two oligonucleotides and their complements were synthesized and kindly provided by Dr. C. Glass, The Scripps Institute: 5'-AATTCTGTTAACTGAGCACAGGATGACCTGGGATCCAGC CCAGCCCCCCCGAGATCTGACTGAGGCCTTCCTGGCA-3' and 5'-AGGCCTTCCTGGCAGAGATGGAGAAGGCCAAGGGGAAC TGA-3'. These oligonucleotides were designed to encode almost all ofthe shortest immunopositive P450IID6/fl-galactosidase construct as two overlapping segments, and silent substitutions were incorporated (under. lined nucleotides) to provide new restriction sites for additional deletion analysis. Equimolar amounts of each oligonucleotide were mixed in ligase buffer (Bethesda Research Laboratories), heated to 100IC for 5 min, and then allowed to cool slowly to room temperature. The resulting double-stranded cDNA was inserted between the EcoRI and HindIII sites of pATH I (T. J. Koerner, Duke University). The sequence of the cloned construct was determined in pATH from the 3' end using a pBR EcoRI primer (New England Biolabs, Beverly, MA) as well as following cloning ofthe insert into pBluescript SK-. Subsequent deletions were made in the pBluescript construct and confirmed by sequence analysis before being transferred to either pATH 1 or pATH 10 . These pATH constructs were also verified by sequencing.
The resulting pATH constructs were transformed into SCS-I cells (Stratagene, Inc.). The cells were cultured and processed for immunoblot analysis as described previously (10) . Polyacrylamide gel electrophoresis employed a discontinuous buffer system containing sodium dodecyl sulfate (SDS) (1 1). The concentration ofmonomer is stated in the figure legends. After electrophoresis the protein content ofthe gels was transferred electrophoretically to nitrocellulose (12) . The nitrocellulose filters were probed with antibody as described previously (3), and bound antibodies were detected as described in the legends to figures.
Affinitypurification ofLKM-1 antibody. The peptide, DPAQPPRDC, and the control peptide IQEEAQCLVEER were synthesized and kindly provided by Dr. Richard Houghten of this institution. The first peptide contains an added carboxyl-terminal cysteine residue for immobilization ofthe peptide to Thiopropyl-Sepharose (Sigma Chemical Co., St. Louis, MO) as described by Parekh et al. (13) . Purification of the antibody followed that outlined by the latter authors. Briefly, 100 MAl of antiserum was incubated with 50.IAI of packed resin for 4 h at room temperature with occasional mixing. The unbound material was recovered for later use. The resin was washed five times with 1 ml of 0.0IM NaPi, pH 7.4, containing 0.1 SM NaCl (PBS). The antibody was eluted in 1 ml of 0.IM citrate buffer containing 0.15M NaCl at pH 3.0 and after removal of the Sepharose, the solution was immediately neutral- (Fig. 1) .
In order to refine the localization of the epitope within the segment encoded by the PvuII-StyI fragment, two overlapping sets of complementary oligonucleotides were synthesized corresponding to this fragment. These contained additional restriction sites resulting from silent substitutions that facilitated the construction of further deletions from either end of the synthetic portion. The fragments produced in this manner (Fig.  1 (Table I ). The smallest segment of this 33-amino acid portion of P4501ID6, which yields an immunoreactive protein when fused with the 33-kD amino-terminal segment of anthranilate synthetase, encodes the amino acid sequence DPAQPPRD (Fig. 2) . This small segment was recognized by 11 ofthe 26 sera (Table I) 15 -mer that included the eight-amino acid "core" sequence DPAQPPRD, and these same sera did not react with the C8-mer and Cl 5-mer (Fig. 1) , which overlapped the positive 15-mer but did not contain the core sequence. In many cases, the intensity of the signal diminished as the segment contained in the pATH construct became shorter, and thus, the differences in the size of the smallest segment which reacted with each antibody could reflect differences in titer that limit detection of their reactivity toward smaller fragments. We suspect that some portion ofthe core sequence, DPAQPPRD, is a necessary part of the epitope recognized by the majority of LKM-I antibodies, but that it alone may not be sufficient for binding ofall LKM-l-positive sera when expressed as a fusion protein and/ or when tested by immunoblotting. Also, the differences seen for these sera regarding their reactivity with segments smaller than the 33-amino acid segment may reflect the influence of the fusion protein on the conformation or accessibility of the epitope.
All ofthe sera, including the four sera that did not recognize the sequence encoded by the PvuII-StyI fragment expressed in pATH, inhibit the binding to the native protein ofan antibody recognizing the core epitope as judged by a competitive radioimmunoassay. The results of this assay are summarized in Table I , and examples are shown in Fig. 3 . In this assay, IgG was purified from the serum ofthe chronic active hepatitis patient, Fig.  3 ). The concentrations required were, however, at the high end of the range seen for these sera (Table I ). In contrast, sera that react with the shortest segment generally inhibit the binding of the reference serum at the lowest concentrations.
Antibodies to HCVproteins. As high as 78% ofLKM-1-positive sera from patients with idiopathic autoimmune chronic active hepatitis have been reported to exhibit antibodies to HCV protein C 100-3 as judged by commercial ELISA procedures (17) (18) (19) (20) . 1 1 of24 LKM-1 sera tested from our panel were shown to be positive for anti-HCV C 100-3 using both the Ortho Diagnostics ELISA and the Chiron Corp. RIBA tests (Table I ). All but two ofthe sera were also positive for the HCV 5-1 -1 protein, and all antisera were negative against superoxide dismutase which is the fusion partner for expression of the recombinant HCV proteins. As shown in Fig. 4 , LKM-1-positive patients whose sera react with the HCV C100-3 protein used in these tests (14) (23) .
A screen of patient sera revealed that 17 of the 20 LKM-1-positive sera tested were also positive for antibodies to HSV-1 (Table I) . When several of these were examined by immunoblotting they were found to react strongly with an extensive array of proteins in lysates from BHK cells infected with HSV-1, whereas this reactivity was not seen for lysates from the uninfected BHK cells. In the example shown in Fig. 5 serum from a LKM-1 positive patient, K.S., is also positive for HSV-1 antibodies as demonstrated by reactivity with a large number of proteins expressed in the cells infected with HSV-1, whereas these proteins are not detected in uninfected cells or by serum from the patient's identical twin (Fig. 5, K .S. twin) who does not have autoimmune hepatitis or exhibit LKM-1 autoantibodies (24) . On the other hand, four LKM-l-positive sera were negative not only when tested using the commercial assay but also when examined by immunoblotting- Table I and example shown in Fig. 5 (S.V.). Thus, most but not all LKM-l-positive sera also exhibit extensive reactivity toward proteins associated with HSV-I infection. In order to determine whether the LKM-1 autoantibody reactive with the small epitope was one of the antibodies that recognize proteins associated with HSV-l infection, we immunoaffinity-purified the antibody using a peptide linked to sepharose. A peptide was synthesized corresponding to the smallest positive fragment, DPAQPPRD, with an additional carboxylterminal cysteine which was used to immobilize the peptide to thiolpropyl sepharose (13) . An LKM-l-positive serum was then incubated with the peptide-Sepharose, and the sequestered LKM-1 antibody was subsequently eluted. As shown in Fig. 6 , the antibody eluted from the peptide-Sepharose reacts strongly with both a 50-kD protein in human liver microsomes as well as with the roughly 40 kD fusion protein containing the sequence DPAQPPRD. In contrast, incubation ofLKM-I -positive sera with a peptide-Sepharose generated with a different peptide, IQEEAQCLVEER, did not lead to isolation ofan antibody which detects these proteins in immunoblotting experiments (data not shown).
As shown in Fig. 6 , the affinity-purified antibody recognizes a high molecular weight protein expressed after infection \\Q( of BHK cells with HSV-1, whereas a protein is not detected by the antibody in lysates from cells which were not infected. The intensity ofthe band is weak and a 10 times greater amount of BHK cell lysate was loaded in this experiment than that shown in Fig. 5 . This analysis does not indicate that the protein recognized is 1E175, however, the estimated size of the protein detected by the affinity-purified antibody, 150±20 kD, is consistent with this possibility. This experiment also demonstrates the ability of the peptide-Sepharose to purify the LKM-1 antibody effectively from antibodies in the serum that recognize other proteins expressed in BHK cells infected with HSV-1.
An ELISA assay was used to determine the extent to which three-repeated adsorptions with the peptide-Sepharose reduced the titer of the autoantibody against human liver microsomes. As shown in Fig. 7 , the titer was reduced by -10-fold whereas it was unaffected by adsorption with the control peptide linked to Sepharose, indicating that this reactivity represents a major component of the LKM-1 autoantibodies present. Immunoblotting demonstrated that the residual LKM-l autoantibodies exhibit reactivity toward the smallest segment ofP4501ID6 expressed as a fusion protein, suggesting that incomplete adsorption contributed to the remaining reactivity (data not shown).
Discussion
The majority, 22 of 26, of LKM-1 -positive sera from patients with autoimmune chronic active hepatitis tested in this study react with a 33-amino acid segment of P450HD6 when it is expressed as a fusion protein. Most the 33-amino acid segment. Although the differences seen between sera in their ability to react with segments shorter than the 33-amino acid sequence is suggestive of differences in the epitope recognized by each sera, the conformation of the core epitope may have been altered by the deletion of flanking sequences and the subsequent replacement of these segments with elements of the fusion protein. This might diminish the binding of the short segment with LKM-I antibodies, and the binding of low titer sera with the short segment might not be detectable for this reason.
A comparison ofthe sequences of P45011D6 with class HID sequences from other species which are known to react with LKM-I antibodies is consistent with this assessment. Gueguen et al. (25) screened a XGTI 1, rat liver cDNA library using three LKM-l-positive sera from children. They characterized four immunopositive, partial cDNAs corresponding to rat P45011D1 and P4501ID2. These clones exhibited a 350-bp region of overlap leading these authors to speculate that the region of overlap encoded the epitope recognized by the three antisera. From the restriction maps presented by these authors (25) , this region of overlap appears to contain rat sequences which align with the epitope identified in our studies. As is shown in Fig. 8 , the sequence ofthe core epitope is conserved in both rat P45011D1 and P450IID2, whereas flanking sequences are seen to diverge. In addition, we have sequenced a partial cDNA which was identified and isolated from a rabbit liver cDNA library by hybridization with the HLD 8.2 cDNA. This fragment encodes amino acids corresponding to 158-427 of human P450IID6, and the fusion protein expressed from this plasmid is also recognized by LKM-1 antibodies (Johnson, E. F., and K. J. Griffin, unpublished observation). The amino acid sequence predicted from the nucleotide sequence is also shown in Fig. 8 for the region corresponding to the epitope.
Specific details regarding the location of the epitope in the structure of P450IID6 have not been determined, although a correspondence with the structure of P450CI, a distantly re-A: (25, 27) and for an immunopositive rabbit cDNA characterized in our laboratory. A consensus sequence is shown on the bottom line. (B) The sequence, GOR47-l, recognized by sera from 87% of nonA, nonB-hepatitis patients tested (28) and two segments of the putative HCV polyprotein (29) are aligned with a portion of the sequence of P450IID6 harboring the LKM-I epitope. lated form of P450, has been predicted by several investigators (30) (31) (32) . Based on these models, the core epitope recognized by LKM-1 antibodies would occur between helices corresponding to G and H ofP450CI which is a protruding loop on the surface of the P450CI enzyme (33) .
The genesis of autoantibodies to such a highly conserved region ofthe protein is unknown. Although host factors such as HLA restriction and the polymorphism of P4501ID6 genes could contribute to an idiotypic autoimmune response that leads to LKM-1 autoantibodies, environmental factors are also thought to contribute to this process. For instance, one of the patients under study in this report has an identical twin. The twins exhibit identical HLA types, and each is an obligate heterozygote for a wild type and a defective allele of P450IID6. Yet only one of the twins is affected by this autoimmune disorder and exhibits LKM-l autoantibodies (24) , suggesting that some environmental factor contributes to the development of disease.
Viruses have been implicated as causative agents in autoimmune disorders (34, 35) , and we have shown that the epitope defined here contains a six-amino acid sequence found in the IE175 protein of HSV-1 (21). Many, but not all, LKM-1-positive patient sera including many of those that react with the short linear sequence exhibit immunoreactivity toward a large number of proteins associated with HSV-l infection ofBHK cells. This group includes the patient who is the only one of a twin pair affected by autoimmune hepatitis. The other twin does not exhibit reactivity with proteins associated with HSV-l infection of BHK cells (Fig. 5) . A peptide corresponding to the short linear epitope was used for the affinity purification of LKM-1 antibodies from a patient's serum. In contrast to the large number of proteins that react with the complete serum, the purified antibody reacts with only a single protein associated with HSV-l infection of BHK cells. This does not confirm that LKM-1 antibodies react with IE175, but it does illustrate the potential for cross recognition of proteins associated with viral infection.
While such "mimicry" has been suggested to lead to autoimmunity (34, 35) , it seems unlikely that all LKM-1 antibodies arise directly from an immune response to IE 175. First, 4 of20 LKM-1 sera do not exhibit evidence for other antibodies directed toward HSV-1 proteins as judged by a commercial assay, and one of these sera reacts with the smallest, eight-amino acid, core epitope. Secondly, the differences seen between LKM-1 antibodies suggest that although many recognize this short epitope they are generally more reactive toward larger segments of P4501ID6 which do not appear to mimic IE175.
HCV has been implicated as the major causative agent of NonA, NonB-transfusion related hepatitis (14, 36) . Antibodies to HCV proteins have been reported to occur frequently (up to 78%) in LKM-l-positive autoimmune hepatitis patients (17) (18) (19) (20) , whereas the incidence of anti-HCV in other groups of autoimmune liver diseases is less profound (Manns, Gerken, Hess, and Meyer zum Buschenfelde, unpublished data). In our study, anti-HCV-positive patients were found to have, on average, a higher age, lower LKM-I inhibitory titers in the RIA and a lower predominance of females as compared with the anti-HCV-negative patients. This suggests that LKM-1 antibodies may be associated with at least two distinct populations that reflect different origins for this disorder.
HCV has been associated with an autoimmune response to an endogenous antigen of unknown function. Mishiro et al.
(28) identified autoantibodies in the sera of 87% of the nonA-, nonB-hepatitis patients tested that recognize an endogenous protein encoded by a cDNA designated, GOR47-1. 67% of these patients were positive for anti-HCV (C 100-3), and HCVrelated mRNAs were detected in additional patients using a polymerase chain reaction assay. This raises the possibility that HCV contributes to the autoimmune response to P450IID6. Although LKM-l antibodies affinity-purified from the fusion protein derived from the HLD8.2 cDNA do not cross-react with the HCV C100-3 protein, the segment of P45011D6 harboring the epitope recognized by LKM-l antibodies exhibits partial sequence identity with the other segments of the polyprotein encoded by HCV as well as the GOR47-1 autoantigen. Two segments of the polyprotein (29) that are not present in the C 100-3 or 5-1-1 protein (37) exhibit partial sequence identity with P450IID6 (Fig. 8) . One significantly overlaps the core epitope whereas the other is found in the region that flanks the core epitope in the 33-amino acid immunoreactive segment. Moreover, five of six amino acids in a segment ofthe GOR47-1 epitope occur adjacent to the epitope defined in this study for LKM-I antibodies in the sequence ofP450IID6 (Fig. 8) . These similarities suggest a potential for immune cross-recognition between P45011D6 and the HCV polyprotein as well as the GOR47-1 protein which could be related to the occurrence of LKM-l autoantibodies in patients with autoimmune hepatitis that are seropositive for anti-HCV.
Future studies will have to evaluate the role ofeither HSV-l or HCV in the etiology of autoimmune liver disease. In addition, work is in progress to define T cell epitopes for P45011D6, and the constructions made in this study will be useful for this purpose. It will be interesting to determine whether the amino acid segments that flank the core epitope and display identity with HCV and GOR47-1 represent T cell epitopes.
